Where is CVS Health Corporation (CVS) Headed According to Analysts?

CVS Health Corporation (NYSE:CVS) is one of the best affordable healthcare stocks to buy now. CVS Health Corporation (NYSE:CVS) received a rating update from RBC Capital on December 18, with the firm maintaining a Buy rating on the stock with a $93.00 price target.

In addition, JPMorgan lifted the price target on CVS Health Corporation (NYSE:CVS) to $101 from $93 on December 17 and maintained an Overweight rating, adjusting price targets in the healthcare services groups as part of its 2026 outlook. The firm told investors that it sees “some reasons for optimism that managed care estimates are approaching trough levels”, adding that most managed care companies will either reach trough levels in 2026 earnings or have already done so in 2025, with potential for upward revisions going forward.

In a separate development, CVS Health Corporation (NYSE:CVS) updated its financial guidance on December 9, raising its total revenues guidance for the full year 2025 to at least $400.0 billion from at least $397.3 billion. The company also lifted the GAAP diluted earnings (loss) per share guidance range to $0.32 to $0.22 from $0.34 to $0.24, and raised the GAAP operating income guidance range to $4.37 billion to $4.54 billion from $4.29 billion to $4.46 billion.

In addition to its 2025 full-year financial guidance, CVS Health Corporation (NYSE:CVS) also initiated its 2026 full-year financial guidance with total revenues of at least $400.0 billion and a GAAP operating income guidance range of $13.26 billion to $13.60 billion. Adjusted EPS guidance range for the year was $7.00 to $7.20, with a cash flow from operations guidance of at least $10.0 billion. CVS Health Corporation (NYSE:CVS) anticipates to attain a mid-teens Adjusted EPS CAGR through 2028, supported by continued strong performance in its business collection.

CVS Health Corporation (NYSE:CVS) is a health solutions company that operates in four segments: healthcare benefits, health services, pharmacy & consumer wellness, and corporate/other.

While we acknowledge the potential of CVS as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.